Alliances and Partnerships

bioMérieux forges partnerships across the globe to drive advances in diagnostics. By working with biotech firms, researchers, biologists and physicians, we remain at the cutting edge of the latest medical, scientific and technological developments.

Joint Research Units

Joint research units bring employees of private companies together with laboratory researchers and doctors working in the public sector. Their purpose is to carry out a long-term project based on the complementary expertise of each team: for example, collaborating with hospital teams allows closer proximity to patients as well as access to new “targets” (viruses, resistant bacteria, etc.). These joint units may develop technologies and instruments or conduct basic research in a wide variety of disciplines: genetics, nanotechnologies, cancer studies and protein engineering.

• Fudan University Cancer Hospital in Shanghai (China): cancer
• Lyon Civil Hospitals - HCL (France): inflammation, septic shock and cancer
• Atomic Energy Commission - CEA (France): Saclay (protein engineering) and LETI (Laboratory for Electronics and Information Technology) in Grenoble (microsystems)

Network of Laboratories

bioMérieux has entered into a number of specific research agreements with academic and state-run institutions in several countries. Valorization of their results is ensured through operating agreements.

• National Institute of Health (United States): infectious diseases
• Centers for Disease Control (United States): infectious diseases
• Mayo Clinic (United States): cancer
• Massachusetts General Hospital Cancer Center (United States)
• Harvard Medical School (United States): cancer
• Baylor College of Medicine (United States): cancer
• University of Texas MD Anderson Cancer Center (United States)
• Public Health Research Institute ( United States): infectious diseases
• University of Sunderland (GB): infectious diseases
• University College of Dublin (Ireland): food safety
• National Center for Scientific Research - CNRS (France)
• National Institute for Health and Medical Research - INSERM (France)
• Pasteur Institute (France): infectious diseases
• Lyonbiopôle technology cluster (France): infectious diseases

Infectious diseases: we work on the rapid identification of microorganisms and the study of their resistance to antibiotics, as well as host resistance to infections.

• Kainos (Japan): bacterial resistance markers for staphylococcal infections

Cancer: bioMérieux has collaboration agreements for the discovery and validation or molecular and proteomic biomarkers, in particular for early screening and predicting treatment effectiveness.

• ExonHit (France): breast, colon and prostate cancer
• ProteoSys (Germany): prostate cancer

Instruments and technologies: we collaborate with numerous micro and nanotechnology companies to develop platforms that are increasingly automated, portable and adapted to diagnostics.

• Affymetrix (United States): DNA chips for the discovery of biomarkers
• Cepheid (United States): diagnostic tests for sepsis
• ReLIA (United States): rapid tests
• Quidel (United States): rapid tests
• Hitachi High-Technologies (Japan): new microbiology and molecular biology systems
• DiagnoSwiss (Switzerland): electrochemical chips

Microbiological food safety monitoring: adapt our solutions to the microbiological monitoring of food safety.

We also develop partnerships that grant the use of our patents beyond our areas of strategic focus and outside of in vitro diagnostics, in the field of therapeutics, for example. bioMérieux licenses our key technologies (BOOM technology for the extraction of nucleic acids, NASBA technology for the amplification of nucleic acids, etc.) and our biomarkers (MRSA, EBV, Factor V, Factor II, etc.).